Introduction
Spinal muscular atrophy (SMA), an often fatal autosomal recessive genetic disease, is characterised by the selective degeneration of spinal cord motor neurons, which causes muscle weakness and atrophy. With an incidence of one in 6,000 live births, SMA is the most common genetic cause of infant mortality. Clinically, SMA is characterised by profound muscle weakness, hypotonia and trunk paralysis, and depending on disease severity and age of onset [1] , is classified into 3 main phenotypic subtypes (I-III). To date, there is no cure for SMA, making the development of potential therapies a high priority.
SMA is a monogenic disorder in which the survival of motor neuron (SMN1) gene is mutated or absent in more than 95% of cases [2] . During human evolution a 500kb inverted duplication of the SMN1 locus has given rise to a second copy of the gene, termed SMN2. The SMN2 gene is essentially identical to SMN1 but a translationally silent nucleotide change (C→T) in exon 7 causes the exons' exclusion from SMN2 transcripts [3, 4] . Consequently, only about 10% of the survival motor neuron 2 (SMN2) protein is functional, while the other 90% is truncated and unstable [5] . The occurrence of multiple SMN2 gene copies in patient groups correlates with increased full-length SMN transcripts, greater amounts of functional protein, and reduced disease severity [6, 7] . Therefore, increasing SMN protein levels in SMA patients presents a feasible treatment approach, and has previously improved the phenotype and survival rates in SMA animal models [8] .
While several candidate therapeutic strategies targeting SMN levels have been developed to treat SMA, they have been of limited success.
For example, histone deacetylase (HDAC) inhibitors, antisense oligonucleotides, direct viral delivery, neuroprotective factors and exercise have all showed promise in preclinical trials [8] [9] [10] [11] [12] [13] . In addition, several HDAC inhibitors, phenylbutyrate and valproic acid have failed to show any significant clinical benefits in SMA patients (reviewed in [14] ). Therefore, there is a need to develop and assess new approaches to treat SMA.
In an earlier study, recombinant SMN was fused to the neuronal targeting diphtheria toxin fragment (TTC-DTx) and evaluated for cell transduction in primary neuronal cultures [15] .
Whilst this approach proved unsuccessful, and cells failed to take up exogenous SMN protein, it highlighted a concept whereby exogenous SMN protein could be delivered to neurons if a suitable cell targeting peptide was available.
In this respect, the 11 amino acid TAT peptide, which is derived from the HIV-1 TAT protein can mediate the efficient cellular transduction of protein cargos in vitro [16] . Moreover, TAT-fused peptides (and related peptides; e.g. Arginine-9; R9) can cross the blood brain barrier (BBB) and impart therapeutic benefits in animal models of disease [17] [18] [19] .
Therefore, in this study, we investigated the feasibility of related TAT peptides (TATκ and R9) to deliver recombinant SMN protein to neurons. In doing so, we developed a mammalian adenoviral vector secretory expression system to generate SMN protein and then assessed the delivery potential of SMN fused to TATκ to enter neurons.
Experimental procedures
Rat primary cortical neuronal cell cultures All animal procedures were approved by the
University of Western Australia Animal Ethics
Committee. Establishment of cortical cultures was as previously described [20] . Briefly, cortical tissue from E18 to E19 Sprague-Dawley rats were dissociated in Dulbecco's Modified Eagle Medium (DMEM; Invitrogen, Melbourne, Australia) supplemented with 1.3 mM L-cysteine, 0.9 mM NaHCO 3 , 10 U/ml papain (Sigma, St. Louis, MO, USA) and 50 U/ml DNaseI (Sigma) and washed in cold DMEM/10% horse serum. Before seeding, wells (96 well microtitre plate; Nalge Nunc International, Thermo Fisher Scientific, Waltham, MA, USA) were coated with poly-D-lysine overnight (50 ml/well: 50 μg/ml; 70 -150K, Sigma). Excess poly-D-lysine solution was then removed and replaced with Neurobasal (containing 2% B27 supplement; 4% foetal bovine serum; 1% horse serum; 62.5 mM glutamate; 25 mM 2-mercaptoethanol; 10 μg/ml streptomycin and 10 mg/ml penicillin).
Neurons were plated to obtain approximately 10,000 viable neurons in each well on day in vitro 12. Neuronal cultures were maintained in a CO 2 incubator (5% CO 2 , 95% air balance, 98% humidity) at 37°C. On day in vitro 4, one third of the culture medium was removed and replaced with fresh Neurobasal/2% B27 containing the mitotic inhibitor cytosine arabinofuranoside
(1 μM final concentration; Sigma). On day in vitro 8, one half of the culture medium was replaced with Neurobasal/2% B27.
Generation of fibronectin fused constructs
Relevant DNA sequences for each of the construct components are shown in Table 1 .
Briefly, the rat fibronectin sequence was fused to either a TATκ-HA or R9-HA sequence.
Constructs containing an SMN or GFP sequence were generated with a 6xHIS sequence for protein purification and as an epitope for detection by western blot analysis.
Cell maintenance, differentiation and transfection HEK293, U251 and SH-SY5Y cells were maintained in DMEM containing penicillin (10 µg/ml), streptomycin (10 µg/ml) and foetal calf serum (FCS; 5-10%; heat-inactivated), and incubated at 37°C in a 5% CO 2 incubator.
The differentiation of SH-SY5Y cells using retinoic acid (15 μM; 5 days) has previously been described [21] . 
PI3-kinase inhibition apoptotic model
Assessment of the anti-apoptotic function of SMN using the phosphatidylinositol-3 kinase (PI3-kinase) inhibitor, LY294002 (Sigma), has previously been described [21] . Briefly, LY294002 was diluted in serum free media to a final concentration of 25 μM prior to addition to differentiated SH-SY5Y cells.
Cell viability assessment
Cell viability was assessed using the MTS assay (Promega, Madison, WI, USA). The MTS assay measures the cellular conversion of tetrazolium to the water-soluble formazan product, which is detected spectrophotometrically at 495 nm.
Protein extraction and western blotting
Proteins were extracted from cultured cells using RIPA lysis buffer (1% NP-40, 0.1% SDS, 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.5% sodium deoxycholate and 1 mM EDTA). Western blotting has been described previously [21] . Briefly, membranes were blocked in PBS-Tween 20 (0.1%) containing ovalbumin (1 mg/ml) for 1 hour and incubated overnight with SMN
(1:3000; Santa Cruz, Santa Cruz, CA, USA), HIS
(1:2000; Santa Cruz) or β-tubulin (1:10000; Santa Cruz) primary antibodies diluted in PBS-T (0.1%) plus ovalbumin (1 mg/ml).
Proteins were detected using a HRP complexed secondary antibody (1:15000-1:35000 donkey anti-rabbit/sheep anti-mouse; GE Healthcare, Piscataway, NJ, USA), and visualised using ECL plus detection reagent (GE Healthcare).
Quantification and band densitometry of western blots was undertaken using ImageJ (NIH, Bethesda, MD, USA) software. 
Statistics
Statistical differences between experimental groups were determined by ANOVA followed by post-hoc Fischer's protected least significant difference (PLSD) test. P < 0.05 was considered statistically significant. Unless otherwise stated, all experiments were conducted at least three times.
Results
Recombinant TAT-GFP is capable of transducing rat cortical neurons Given the high recombinant TAT-GFP protein recovery rates we obtained from E.
coli, we postulated that GFP may enhance SMN protein recovery. Therefore, we generated and expressed the SMN protein as a larger fusion protein with GFP (TAT-SMN-GFP). However, although TAT-SMN-GFP fusion protein yields were significantly increased as revealed by SDS-PAGE analysis, two distinct protein bands were detected ( Figure 2C ). Western blot analysis using a specific anti-SMN antibody detected multiple bands similar to and larger than the molecular weight of the SMN protein ( Figure 2D ).
These results suggest that the TAT-SMN-GFP fusion protein may be subject to cleavage, degradation or incomplete translation in E. coli.
Generation of recombinant SMN fused to the fibronectin signal peptide
The development of a plasmid vector capable of secreting TAT-fused GFP from HEK293 cells has been previously described [25] . The study determined that efficient secretion of intact TAT-fused proteins requires the furin proteolytic sites within TAT to be mutated. Hence, the original TAT sequence YGRKKRRQRRR was modified to YARKAARQARA (referred to as TATκ; [25] ). Importantly, TATκ was shown to retain protein transduction efficiency. In our system, we used the adenoviral pShuttle plasmid expression vector, which incorporates the woodchuck post-transcriptional regulatory element (WPRE) for high-level expression [26] . GFP or SMN protein was fused to the rat fibronectin (FIB) signal peptide sequence and either the TATκ or R9 CPP sequence ( Figure 3A ).
FIB-CPP-GFP transfected HEK293 cells show a secretory phenotype
To determine if FIB-TATκ-GFP and FIB-R9-GFP secretory constructs induce the characteristic appearance of a secretory protein, HEK293 cells Both the TATκ-GFP and TATκ-SMN proteins were detected in culture supernatants using the HIS antibody and their respective protein specific antibodies ( Figure 4C ).
Recombinant TAT fused proteins can be purified from transduced U251 cell lysates and culture supernatants Recombinant SMN protein derived from human cells, such as U251 cells, are likely to be correctly folded and post-translationally modified, which reportedly is required for full functional activity [28] . Recombinant TATκ-GFP and TATκ-SMN proteins were isolated and purified from culture medium, and from U251 cell lysates, using the 6xHIS tag and Ni 2+ affinity 
Discussion
The most promising therapies currently being developed to treat SMA are aimed at increasing SMN protein levels, indirectly, by redirecting SMN2 splicing or directly, by using viral delivery of an SMN transgene [29, 30] . However, a number of SMA therapies, developed on the basis of promising animal and in vitro experimentation, have either failed to provide therapeutic benefits or remain in preclinical testing [31, 32] . Thus, it is imperative to explore and develop novel therapeutic approaches.
One possibility involves the delivery of SMN protein directly to the central nervous system using CPPs, such as TAT, which are capable of transporting their cargo across the bloodbrain barrier (BBB) and into cells of the central nervous system [33] .
In the present study, we first confirmed that the TAT peptide can promote the transduction of the GFP protein across neuronal membranes.
Consistent with previous studies [33] [34] [35] we [36] , and has shown potential in the treatment of neurodegenerative disorders [37] [38] [39] . Fusion of a therapeutic protein to the fibronectin signal peptide, an endoplasmic reticulum targeting motif, triggers its secretion via the constitutive pathway.
Secretion is initiated following cleavage of the signal peptide and is completed by molecular trafficking events, which deliver the protein to the plasma membrane [40] .
In deciding a CPP to adopt for the secretary system, we chose to compare the action of a modified TAT peptide (TATκ) and R9.
While the TATκ peptide is not cleaved by the convertase enzyme furin, R9 is cleaved by this enzyme [41] . We observed that purified TATκ-GFP or 
